Uncategorized
The Quinze-Vingts Hospital and GenSight Biologics Announce a First Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France
PARIS--(BUSINESS WIRE)--Regulatory News: The National Eye Hospital (CHNO) of the Quinze-Vingts in Paris and GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the French Competent Authority, the National Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM), g